JP7094226B2 - 医薬品有効成分用のタンパク質をベースにした添加物 - Google Patents
医薬品有効成分用のタンパク質をベースにした添加物 Download PDFInfo
- Publication number
- JP7094226B2 JP7094226B2 JP2018556473A JP2018556473A JP7094226B2 JP 7094226 B2 JP7094226 B2 JP 7094226B2 JP 2018556473 A JP2018556473 A JP 2018556473A JP 2018556473 A JP2018556473 A JP 2018556473A JP 7094226 B2 JP7094226 B2 JP 7094226B2
- Authority
- JP
- Japan
- Prior art keywords
- api
- protein
- additive
- solvent
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008186 active pharmaceutical agent Substances 0.000 title claims description 411
- 239000000654 additive Substances 0.000 title claims description 320
- 102000004169 proteins and genes Human genes 0.000 title claims description 317
- 108090000623 proteins and genes Proteins 0.000 title claims description 317
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 395
- 239000000203 mixture Substances 0.000 claims description 316
- 235000018102 proteins Nutrition 0.000 claims description 314
- 239000002904 solvent Substances 0.000 claims description 303
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 278
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 207
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 202
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 188
- 230000000996 additive effect Effects 0.000 claims description 186
- 238000009472 formulation Methods 0.000 claims description 182
- 150000007524 organic acids Chemical class 0.000 claims description 149
- 235000019253 formic acid Nutrition 0.000 claims description 140
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 139
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 113
- 229940098773 bovine serum albumin Drugs 0.000 claims description 105
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 102
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 99
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 93
- 239000008273 gelatin Substances 0.000 claims description 92
- 229920000159 gelatin Polymers 0.000 claims description 92
- 108010010803 Gelatin Proteins 0.000 claims description 91
- 235000019322 gelatine Nutrition 0.000 claims description 90
- 235000011852 gelatine desserts Nutrition 0.000 claims description 90
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 75
- 229940127557 pharmaceutical product Drugs 0.000 claims description 73
- 150000001413 amino acids Chemical class 0.000 claims description 67
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 66
- 238000001035 drying Methods 0.000 claims description 64
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 claims description 62
- 229960004500 flubendazole Drugs 0.000 claims description 62
- -1 glyceofrubin Chemical compound 0.000 claims description 61
- 239000011877 solvent mixture Substances 0.000 claims description 45
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 44
- 235000005985 organic acids Nutrition 0.000 claims description 44
- 230000004071 biological effect Effects 0.000 claims description 41
- 229920001223 polyethylene glycol Polymers 0.000 claims description 38
- 238000001694 spray drying Methods 0.000 claims description 34
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 32
- 229960004130 itraconazole Drugs 0.000 claims description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims description 31
- 238000004108 freeze drying Methods 0.000 claims description 29
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 29
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 26
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 26
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 24
- 229960000623 carbamazepine Drugs 0.000 claims description 24
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 23
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 23
- 229960001597 nifedipine Drugs 0.000 claims description 23
- 229960002036 phenytoin Drugs 0.000 claims description 23
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 22
- 229960000905 indomethacin Drugs 0.000 claims description 22
- 229960004125 ketoconazole Drugs 0.000 claims description 22
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 19
- 239000007962 solid dispersion Substances 0.000 claims description 17
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 229960001722 verapamil Drugs 0.000 claims description 16
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 claims description 13
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 13
- 229960004099 azithromycin Drugs 0.000 claims description 13
- 229960002979 iopanoic acid Drugs 0.000 claims description 13
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 12
- 229960003529 diazepam Drugs 0.000 claims description 12
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 12
- 229960000815 ezetimibe Drugs 0.000 claims description 12
- 229960000746 testosterone undecanoate Drugs 0.000 claims description 11
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004420 aceclofenac Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 7
- 229960001680 ibuprofen Drugs 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 3
- 238000004611 spectroscopical analysis Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002297 fenofibrate Drugs 0.000 claims description 2
- 229960001852 saquinavir Drugs 0.000 claims description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 2
- 229960005107 darunavir Drugs 0.000 claims 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 136
- 235000011054 acetic acid Nutrition 0.000 description 129
- 235000019441 ethanol Nutrition 0.000 description 79
- 239000000243 solution Substances 0.000 description 75
- 239000000306 component Substances 0.000 description 68
- 239000000843 powder Substances 0.000 description 37
- 230000006870 function Effects 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000002245 particle Substances 0.000 description 31
- 229920000642 polymer Polymers 0.000 description 31
- 239000012460 protein solution Substances 0.000 description 30
- 239000000126 substance Substances 0.000 description 30
- 239000007909 solid dosage form Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- 102000009027 Albumins Human genes 0.000 description 26
- 108010088751 Albumins Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 22
- 239000012052 hydrophilic carrier Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 238000012545 processing Methods 0.000 description 15
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 14
- 239000002775 capsule Substances 0.000 description 14
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 14
- 229960000311 ritonavir Drugs 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000000576 coating method Methods 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 10
- 230000000172 allergic effect Effects 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 239000008240 homogeneous mixture Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229960002009 naproxen Drugs 0.000 description 10
- 239000007921 spray Substances 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000000717 retained effect Effects 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 239000005862 Whey Substances 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 240000008042 Zea mays Species 0.000 description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 235000005822 corn Nutrition 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 5
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 5
- 108010084695 Pea Proteins Proteins 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 239000011247 coating layer Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 5
- 229960002867 griseofulvin Drugs 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 5
- 229960004454 oxfendazole Drugs 0.000 description 5
- 235000019702 pea protein Nutrition 0.000 description 5
- 239000006069 physical mixture Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000019710 soybean protein Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001839 systemic circulation Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 5
- 235000007319 Avena orientalis Nutrition 0.000 description 4
- 241000209763 Avena sativa Species 0.000 description 4
- 235000007558 Avena sp Nutrition 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 241000209056 Secale Species 0.000 description 4
- 235000007238 Secale cereale Nutrition 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 229920002494 Zein Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 235000009120 camo Nutrition 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 235000005607 chanvre indien Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000011487 hemp Substances 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 235000021239 milk protein Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960003862 vemurafenib Drugs 0.000 description 4
- 239000005019 zein Substances 0.000 description 4
- 229940093612 zein Drugs 0.000 description 4
- 235000017060 Arachis glabrata Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 description 3
- 235000018262 Arachis monticola Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 240000004713 Pisum sativum Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 108010055615 Zein Proteins 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004777 protein coat Anatomy 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OSNIIMCBVLBNGS-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one Chemical compound CN(C)C(C)C(=O)C1=CC=C2OCOC2=C1 OSNIIMCBVLBNGS-UHFFFAOYSA-N 0.000 description 1
- JLIDVCMBCGBIEY-UHFFFAOYSA-N 1-penten-3-one Chemical compound CCC(=O)C=C JLIDVCMBCGBIEY-UHFFFAOYSA-N 0.000 description 1
- KJUCPVIVNLPLEE-UHFFFAOYSA-N 2,6-difluoro-n-[2-fluoro-5-[5-[2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]-2-propan-2-yl-1,3-thiazol-4-yl]phenyl]benzenesulfonamide Chemical compound S1C(C(C)C)=NC(C=2C=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C(F)=CC=2)=C1C(N=1)=CC=NC=1NC(C=N1)=CC=C1N1CCOCC1 KJUCPVIVNLPLEE-UHFFFAOYSA-N 0.000 description 1
- BVGDAZBTIVRTGO-UONOGXRCSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2s)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine Chemical compound C1([C@@H](C)OC=2C(N)=NC=C(C=2)C2=CN=C(C=C2OC)N2[C@H](CNCC2)C)=C(Cl)C=CC(F)=C1Cl BVGDAZBTIVRTGO-UONOGXRCSA-N 0.000 description 1
- SFXVRNLGOSAWIV-UHFFFAOYSA-N 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholin-4-ylprop-1-ynyl)pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C(=O)NC1=CC=C(C=C1)COC)C#CCN1CCOCC1)C1(CC1)C SFXVRNLGOSAWIV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 1
- UQONAEXHTGDOIH-AWEZNQCLSA-N O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 Chemical compound O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 UQONAEXHTGDOIH-AWEZNQCLSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 231100001125 band 2 compound Toxicity 0.000 description 1
- 231100001127 band 4 compound Toxicity 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000000612 dual polarization interferometry Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000005804 musculo-skeletal problem Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 125000001741 organic sulfur group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003380 quartz crystal microbalance Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063138 sporanox Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009283 thermal hydrolysis Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- 少なくとも10アミノ酸の長さ-モノマー当たり-のタンパク質を含むタンパク質組成物又はその加水分解産物から得られた、タンパク質をベースにした添加物と;
- 医薬品有効成分(API)と
を含む製剤であって;
前記タンパク質をベースにした添加物及び前記APIが共に、実質的に非晶質であり、
実質的に均質な混合物を形成することを特徴とする製剤に関する。
- 少なくとも10アミノ酸の長さ-モノマー当たり-のタンパク質を含むタンパク質組成物又はその加水分解産物から得られた、タンパク質をベースにした添加物と;
- 医薬品有効成分(API)と
を含む医薬品製剤を生成するための方法であって;
前記タンパク質をベースにした添加物及び前記APIが共に、実質的に非晶質であり、実質的に均質な混合物を形成し;少なくとも:
(a) 溶媒を使用して前記APIを溶解して溶液を得る工程と;
(b) 工程(a)の溶液を乾燥して、実質的に非晶質である粉末を得る工程と
を含むことを特徴とする方法に関する。
(i) 溶媒を使用してタンパク質組成物又はその加水分解産物を溶解して溶液を得る工程;及び
(ii) 工程(i)の溶液を乾燥して、前記タンパク質をベースにした添加物を得る工程
を通して調製される。
- 同じ溶媒中に一緒に溶解され、乾燥され、それによって前記医薬品製剤を形成するか;
- 同じ又は異なる溶媒中に別々に溶解され、その後、一緒に乾燥され、それによって前記医薬品製剤を形成するか;
- 同じ又は異なる溶媒中に溶解され、別々に乾燥され、その後、混合され、それによって前記医薬品製剤を形成するか
のいずれかであることを提供する。
- 少なくとも10アミノ酸の長さ-モノマー当たり-のタンパク質を含むタンパク質組成物又はその加水分解産物から得られた、タンパク質をベースにした添加物と;
- 医薬品有効成分(API)と
を含む製剤であって;
前記タンパク質をベースにした添加物及び前記APIが共に、実質的に非晶質であり;好ましくは完全に非晶質であることを特徴とする製剤に関する。有利には、前記タンパク質をベースにした添加物及び前記APIは、実質的に均質な混合物を形成し、より好ましくは、完全に均質な混合物を非晶質固体分散体(ASD)として形成する。
は、ほとんどの粉末又は固体分散体に関して実験により(例えば、X線粉末回折分光法(XRD)、示差走査熱量測定(DSC))検証することができる。
- 少なくとも10アミノ酸の長さ-モノマー当たり-のタンパク質を含むタンパク質組成物又はその加水分解産物から得られた、タンパク質をベースにした添加物と;
- 医薬品有効成分(API)と
を含む医薬品製剤を生成するための方法であって;
前記タンパク質をベースにした添加物及び前記APIが共に、実質的に非晶質であり;少なくとも:
(a) 溶媒を使用して前記APIを溶解して溶液を得る工程と;
(b) 工程(a)の溶液を乾燥して、実質的に非晶質である粉末を得る工程と
を含むことを特徴とする方法に関する。
(i) 溶媒を使用して、タンパク質組成物又はその加水分解産物を溶解して、溶液を得る工程;及び
(ii) 工程(i)の溶液を乾燥して、前記タンパク質をベースにした添加物を得る工程
を通して調製されることを提供する。
-同じ溶媒中に一緒に溶解され、乾燥され、それによって前記医薬品製剤を形成するか;
-同じ又は異なる溶媒中に別々に溶解され、その後、一緒に乾燥され、それによって前記医薬品製剤を形成するか;
- 同じ又は異なる溶媒中に溶解され、別々に乾燥され、その後、混合され、それによって前記医薬品製剤を形成するか
のいずれかであることを提供する。
(i) 少なくとも1種の追加の(タンパク質をベースにしない)添加物、安定化剤、矯味剤成分、コーティング層、水分防止成分、界面活性剤等、追加の成分を製剤に添加する工程;
(ii) 前記タンパク質をベースにした添加物の性質;例えば異なるタンパク質、異なるタンパク質源、異なるタンパク質組成物等の選択を、最適化することにより、製剤の過飽和の速度及び程度を制御する工程;
(iii) 例えば吸収(即ち、血液循環に進入するAPIの速度及び濃度の制御)、遊離(即ち、製剤からのAPI放出の瞬間及び場所の制御)、分布(即ち、身体の体液及び組織の全体にわたるAPIの分散の促進又は予防)、代謝化(即ち、身体の体液及び組織内でのAPIの消化の予防又は促進)、及び排泄(即ち、APIが不可逆的に体組織に蓄積され得るいくつかの場合に、吸収されていないAPIを身体から安全に除去すること)が制御されるよう、製材の薬物動態特性を誘導するためにタンパク質添加物に対して選択的調節を実施する工程;
(iv) 溶媒、溶液、及び乾燥方法を変化させる等、加工方法を最適化することにより、製剤の性質及び加工コスト、時間、及び/又は規模を調節する工程。
好ましいタンパク質源の決定
自然の全ての領域から(例えば、動物、野菜、及び微生物由来)の様々なタンパク質は、有機酸に溶解し易く、その後、(噴霧又は凍結)乾燥され、液体系に再溶解される。
タンパク質の構造に対する加工技術(噴霧乾燥及び凍結乾燥)の効果の決定
タンパク質をベースにした添加物を得るのに使用されるタンパク質の天然構造に対する、加工技術(即ち、溶媒及び乾燥方法)の効果について、検証した。
タンパク質の生物活性に対する加工技術の影響の検証
実施例2は、ギ酸中での最長8時間のインキュベーションが、BSAの4成分構造に著しい影響を及ぼさないようであることを、既に明らかにした。しかし本発明の目的で、タンパク質をベースにした添加物がその生物活性を少なくとも部分的に保持する場合が好ましい。より好ましくは、その生物活性を少なくとも部分的に、胃腸系内に存在する低pH値条件で保持する場合である。この生物活性は、過飽和状態を実現し且つ前記過飽和状態を長期間にわたり維持するのに有益である可能性がある。
製剤の過飽和状態に対する、タンパク質をベースにした添加物の影響の決定
様々なタンパク質源からの種々のタンパク質又はタンパク質組成物を、様々な濃度で調製して、過飽和状態を実現し且つ前記過飽和状態を維持することに関し、製剤中に含まれるタンパク質をベースにした添加物の影響の程度を評価した。高度な過飽和の実現は、前記製剤中に含まれるAPIの、改善されたバイオアベイラビリティに関するインジケータと見なすことができる。
ゼラチンをベースにした添加物を含む製剤の構造特性
3種のゼラチンをベースにした添加物を、加工後に、前記添加物を含む製剤の構造特性(例えば、固体状態及び粉末粒径)を更に評価するために保持した;特に、ブルーム=50gであるブタの皮膚のゼラチン、ブルーム=75gであるブタの皮膚のゼラチン、ブルーム225gであるウシの骨のゼラチンであった。フルベンダゾールを、再びモデルAPIとして選択し、ギ酸は溶媒として働き、噴霧乾燥を乾燥方法として選択した。
BSAをベースにした添加物を含む(噴霧乾燥した)製剤の構造特性
実施例5と同様に、BSAをベースにした添加物を含む製剤の構造特性を、加工後に評価した。BSAタンパク質組成物用の原材料を、ウシ由来のものから抽出した。フルベンダゾールをモデルAPIとして再び選択し、ギ酸は溶媒として働き、噴霧乾燥を、乾燥方法として選択した。BSA試料は全て、4つの異なる(%/%)比;即ち、[90-10]、[80-20]、[70-30]、及び[60-40]の添加物/API(%)に関して、フルベンダゾールと一緒にギ酸に溶解した。次に、タンパク質-API溶液を、同一条件下で噴霧乾燥して、粉末製剤を非常に高い収率で得た。標準較正パラメーターを設定するための参照試料は、APIなしでギ酸に溶解したBSAから構成された。
BSA又はゼラチンをベースにした添加物を含む(噴霧乾燥した)製剤の溶解プロファイル
非晶質状態を示す、実施例5及び6から得た製剤を、それらの溶解度及び溶解速度に関して試験をし;即ち、ブタのゼラチンのブルームが50g又は225g: FLU(それぞれ80:20%又は90:10%の比)、及びBSA(70~90%): FLU(30~10%)であった。
タンパク質をベースにした添加物とポリマーをベースにした添加物との組合せ、及び前記組合せを含む噴霧乾燥した製剤の構造特性
第1のAPI、及び第2のポリマーをベースにした添加物又はタンパク質をベースにした添加物、或いはタンパク質とポリマーをベースにした添加物との組合せを含む、種々の製剤の構造特性を分析し比較した。
可溶性が不十分なAPIに対する適合性の検証
種々の可溶性が不十分なAPIを、溶解度向上剤としてのタンパク質をベースにした添加物の効果を評価するために選択した。最初に、クラスII(即ち、可溶性が不十分であり、透過性が高い)を最も代表すると見なされる、クラスIIに属する様々なAPIの選択を行った。APIのそれぞれに関し、添加物と組み合わせて製剤を生成し、その後、試験用に被膜流延した。最適なAPI/添加物濃度を、実施例4の結果に基づいて選択し、即ち、各製剤は、20%のAPI及び80%のBSA(w/w)を含んでいた。下記のAPIを選択した:イブプロフェン、インドメタシン、ナプロキセン、フェニトイン、ニフェジピン、グリセオフルビン、及びベラパミル。
固体分散体に最適な生成パラメーターの決定
添加物としての、BSAによるAPIの非晶質固体分散体の開発は、様々な生成パラメーターを用いた噴霧乾燥を介して試料を生成することにより試験をした。2種のAPIをクラスIIのAPI群から選択して、モデルAPIとして働かせ;即ち、ベムラフェニブ及びイトラコナゾールである。各製剤ごとに、6種の試料を生成し、したがって合計で12種の試料が得られた。
・ 示差走査熱量測定(DSC)法を、被膜の非晶質性の決定のために使用した。試料10%及び20%のAPI(参照試料1、2、4、及び5)を含む試料は、最も将来性あるDSC結果を実証し、結晶融解ピークは存在しない。
・ アッセイ値は、HPLCを使用して決定した。全ての6種の試料に関し、89~103%の間の良好なアッセイ値が観察された。試料調製手順を検証するために、スパイクされたプラセボ試料を、10/90%w/wのAPI/BSAを含有させて調製した。APIのスパイク量は検索することができ、したがって試料調製は適切と見なした。
・ 加速スクリーニング安定性試験は、全ての試料が、25℃及び60%の部屋の湿度(RH)で1カ月間保存されたときに良いテクスチャ及び良好な流動を実証することを示したが、いくらかの凝集が、40℃及び75%のRHで観察された。
・ 6種の試料の全ては将来性あるDSC結果を実証し、融解ピークは存在しなかった。
・ 6種の試料の全てに関し、88~91%の間のアッセイの値が測定された。
・ 全ての試料は、25℃及び60%RHで1カ月間保存したときに、良いテクスチャ及び良好な流動を実証したが、いくらかの凝集が、40℃及び75%RHで観察された。
比較溶解試験
添加物としてのBSAの存在下、APIの噴霧乾燥した粉末のバイオアベイラビリティを、実施例9から選択された最適なパラメーターを使用して試験した。4種の試料を、2種の異なるAPIで、即ちベムラフェニブ及びイトラコナゾールで製造し、API/添加物濃度(w/w%)を変化させた。
噴霧乾燥した製剤の濡れ性の改善
実施例10及び実施例11を行うとき、イトラコナゾール等の濡れ性が不十分なある特定のAPIは、(非晶質)固体分散体に加工するための溶媒としてギ酸を使用するときに100%の溶解を実現するのに高レベルの撹拌(agitation)(例えば、撹拌(stirring))を必要とすることが観察された。親水性担体の、製剤への添加は、この問題を解決した。
ゼラチンをベースにした添加物を含む(凍結乾燥した)製剤の構造特性
添加物としてゼラチンを用いたAPI用の非晶質固体分散体の開発は、様々な生成パラメーターで凍結乾燥を介して試料を生成することにより、試験をした。10種の可溶性が不十分なAPIを、クラスIIのAPI群から選択して、モデルAPIとして働かせた;即ち、カルバマゼピン、シンナリジン、ダルナビル(エタノレート)、ジアゼパム、フェノフィブラート、グリセオフルビン、インドメタシン、カテコナゾール、ナプロキセン、及びニフェジピンである。タンパク質をベースにした添加物は全て、ブタの皮膚から抽出されたゼラチン(ブルーム=50g)をベースにし;全てはRousselot(登録商標)製であった。
ゼラチンをベースにした添加物を含む(凍結乾燥した)製剤の溶解プロファイル
種々の可溶性が不十分なAPIを、クラスIIのAPI群から選択して、溶解度を高めるための、タンパク質をベースにした添加物としてのゼラチンの効果を評価した。実施例13で詳述した方法により生成された10種の試料を、更に試験するために選択し;即ち、カルバマゼピン、シンナリジン、ダルナビル(エタノレート)、ジアゼパム、フェノフィブラート、グリセオフルビン、インドメタシン、ケトコナゾール、ナプロキセン、及びニフェジピンを選択した。タンパク質をベースにした添加物は全て、ブタの皮膚(ブルーム=50g)から抽出されたゼラチンであり;その全てはRousselot(登録商標)製であった。
BSAをベースにした添加物を含む(凍結乾燥された)製剤の溶解プロファイル
添加物としてBSAを含む、API用の非晶質固体分散体の開発は、凍結乾燥を介して試料を生成することにより試験をした。イトラコナゾールはモデルAPIとして働いた。
Claims (17)
- - 少なくとも10アミノ酸の長さのタンパク質から成り、ヒト血清アルブミン(HSA)、ウシ血清アルブミン(BSA)、乳清タンパク質、ゼラチンから選択されるタンパク質組成物から得られた、タンパク質をベースにした添加物と、
- 生物医薬品分類システムに従った、クラスII又はクラスIVの医薬品有効成分(API)と
を含む製剤であって、
前記タンパク質をベースにした添加物及び前記APIが、X線粉末回折分光法(XRD)及び/又は示差走査熱量測定(DSC)によって検証して、不均質性及び結晶性を含有しない、完全に均質な非晶質の固体分散体を形成することを特徴とし、
APIの添加物に対する質量比(w/w)が、APIが少なくとも5%及び添加物が最大で95%(5/95)から、APIが最大で50%及び添加物が少なくとも50%(50/50)の間にあり、100%がAPI及び添加物の合計質量と定義される、製剤。 - タンパク質をベースにした添加物が、変性せず、且つ/又はその生物活性の少なくとも一部を保持する、請求項1に記載の製剤。
- APIが、下記のリスト:フルベンダゾール、カルバマゼピン、グリセオフルビン、フェニトイン、ニフェジピン、ベラパミル、アジスロマイシン、ニトロフラントイン、イオパノ酸、イトラコナゾール、イブプロフェン、インドメタシン、グリベンクラミド、ビカルタミド、エゼチミブ、アセクロフェナク、ケトコナゾール、オクスフェンダゾール、リトナビル、フェノフィブラート、シンナリジン、ダルナビル、ジアゼパム、ウンデカン酸テストステロン、又はナプロキセンから選択される、請求項1又は2に記載の製剤。
- 前記APIがフルベンダゾールであり、タンパク質組成物から得られる前記タンパク質をベースにした添加物が、血清アルブミン(HSA、BSA)及び/又はゼラチンである、請求項1から3のいずれか一項に記載の製剤。
- APIの添加物に対する質量比(w/w)が、APIが少なくとも5%及び添加物が最大で95%(5/95)から、APIが最大で40%及び添加物が少なくとも60%(40/60)の間である、請求項1から4のいずれか一項に記載の製剤。
- APIが少なくとも5%及び添加物が最大で95%(5/95)から、APIが最大で30%及び添加物が少なくとも70%(30/70)の間にある、請求項5に記載の製剤。
- APIが少なくとも5%及び添加物が最大で95%(5/95)から、APIが最大で20%及び添加物が少なくとも80%(20/80)の間にある、請求項5に記載の製剤。
- APIが少なくとも10%及び添加物が最大で90%(10/90)から、APIが最大で20%及び添加物が少なくとも80%(20/80)の間にある、請求項5に記載の製剤。
- 請求項1から8いずれか一項に記載の医薬品製剤を生成するための方法であって、少なくとも、
- (a) 溶媒を使用して、クラスII又はクラスIVのAPIを溶解して溶液を得る工程と、
(b) 工程(a)の溶液を乾燥して前記APIを得る工程と
を通してAPIを調製する工程であって、
APIを調製するための溶媒が、有機酸若しくは有機硫黄化合物であり、又は有機酸及び/若しくは有機硫黄化合物を含む溶媒混合物であることを特徴とする工程と、
- (i) 溶媒を使用して、少なくとも10アミノ酸の長さのタンパク質から成り、ヒト血清アルブミン(HSA)、ウシ血清アルブミン(BSA)、乳清タンパク質、ゼラチンから選択されるタンパク質組成物を溶解して溶液を得る工程と、
(ii) 工程(i)の溶液を乾燥して、タンパク質をベースにした添加物を得る工程と
を通して前記タンパク質をベースにした添加物を調製する工程であって、
添加物を調製するための溶媒が、有機酸若しくは有機硫黄化合物であり、又は有機酸及び/若しくは有機硫黄化合物を含む溶媒混合物であることを特徴とする工程と
を含む方法。 - 溶媒が、ギ酸、トリフルオロ酢酸、若しくは酢酸から選択される有機酸であるか、又は前記有機酸の混合物であるか、又はギ酸、及び/若しくはトリフルオロ酢酸、及び/若しくは酢酸から選択される1種若しくは複数の有機酸、並びにアルコール、アセトン、DCM、THF、塩化メチレン、メチルエチルケトン、アセトニトリル、有機硫黄化合物、DMSO、ポリエチレングリコールから選択される少なくとの1種のその他の溶媒を含む溶媒混合物である、請求項9に記載の方法。
- 溶媒混合物が、少なくとも5%の酢酸及び/又はギ酸から最大で90%の酢酸及び/又はギ酸(v/v)を含む、請求項10に記載の方法。
- 溶媒が、有機硫黄化合物である;又は少なくとも1種の有機硫黄化合物と、アルコール、アセトン、DCM、THF、塩化メチレン、メチルエチルケトン、アセトニトリル、DMSO、又はポリエチレングリコールから選択される少なくとも1種のその他の溶媒とを含む溶媒混合物である、請求項9または10に記載の方法。
- 乾燥が、噴霧乾燥、凍結乾燥、真空乾燥、フラッシュ乾燥、パドル乾燥、空気乾燥、凝縮乾燥、及び/又はこれらの組合せによって行われる、請求項9から12のいずれか一項に記載の方法。
- 乾燥が、噴霧乾燥及び/又は凍結乾燥によって行われる、請求項9から13のいずれか一項に記載の方法。
- APIが、下記のリスト:フルベンダゾール、カルバマゼピン、グリセオフルビン、フェニトイン、ニフェジピン、ベラパミル、アジスロマイシン、ニトロフラントイン、イオパノ酸、イトラコナゾール、イブプロフェン、インドメタシン、グリベンクラミド、ビカルタミド、エゼチミブ、アセクロフェナク、ケトコナゾール、オクスフェンダゾール、リトナビル、サキナビル、フェノフィブラート、シンナリジン、ダルナビル、ジアゼパム、ビホナゾール、ウンデカン酸テストステロン、又はナプロキセンから選択される、請求項9から14のいずれか一項に記載の方法。
- 請求項1から8のいずれか一項に記載の製剤中、タンパク質をベースにした添加物として少なくとも10アミノ酸の長さのタンパク質から成り、ヒト血清アルブミン(HSA)、ウシ血清アルブミン(BSA)、乳清タンパク質、ゼラチンから選択されるタンパク質組成物の使用であって、タンパク質をベースにした添加物が、変性せず、且つ/又はその生物活性の少なくとも一部を保持する、使用。
- 医薬として使用するための、請求項1から8のいずれか一項に記載の製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE2016/5302A BE1023653B1 (nl) | 2016-04-29 | 2016-04-29 | Eiwit gebaseerd excipient voor actieve farmaceutische stoffen |
BE2016/5302 | 2016-04-29 | ||
BE2016/5977 | 2016-12-26 | ||
BE201605977 | 2016-12-26 | ||
PCT/EP2017/060143 WO2017186889A1 (en) | 2016-04-29 | 2017-04-28 | Protein based excipient for active pharmaceutical ingredients |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019514932A JP2019514932A (ja) | 2019-06-06 |
JP2019514932A5 JP2019514932A5 (ja) | 2020-04-23 |
JP7094226B2 true JP7094226B2 (ja) | 2022-07-01 |
Family
ID=58699093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556473A Active JP7094226B2 (ja) | 2016-04-29 | 2017-04-28 | 医薬品有効成分用のタンパク質をベースにした添加物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190083629A1 (ja) |
EP (2) | EP4062941A1 (ja) |
JP (1) | JP7094226B2 (ja) |
CN (1) | CN109152842B (ja) |
AU (1) | AU2017256767A1 (ja) |
BR (1) | BR112018072113A2 (ja) |
CA (1) | CA3018812A1 (ja) |
ES (1) | ES2925656T3 (ja) |
IL (1) | IL262568A (ja) |
PT (1) | PT3448435T (ja) |
WO (1) | WO2017186889A1 (ja) |
ZA (1) | ZA201806357B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190099455A (ko) * | 2016-12-23 | 2019-08-27 | 유니버시티 오브 코펜하겐 | 단백질 및 물질의 공동-무정형 형태 |
WO2021111143A1 (en) * | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
CN111821309B (zh) * | 2020-04-30 | 2021-08-24 | 深圳市新阳唯康科技有限公司 | 一种具有改良溶出速度的达芦那韦组合物 |
CN111840255B (zh) * | 2020-07-31 | 2022-03-01 | 北京丰帆生物医药科技有限公司 | 一种维拉帕米温敏缓释制剂及其制备方法和应用 |
CN112176002B (zh) * | 2020-11-10 | 2022-09-02 | 四川大学 | 胶原基酒精发酵促进剂、及其制备方法和应用 |
EP4351523A1 (en) | 2021-06-10 | 2024-04-17 | Lonza Bend Inc. | Spray drying of api in supersaturated solutions with formic acid |
CA3238938A1 (en) | 2021-11-24 | 2023-06-01 | Korbinian LOBMANN | Ternary co-amorphous forms of drugs, proteins, and water-soluble polymers |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508482A (ja) | 1999-09-03 | 2003-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 標的動物に対する水分布システムを通す水−不溶性薬品の投与のための獣医学的調合物 |
JP2007501219A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 薬物及び重合体の固体無定形分散を形成するための噴霧乾燥(スプレードライ)方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
DE4201173C2 (de) * | 1992-01-17 | 1998-10-29 | Alfatec Pharma Gmbh | Akutarzneimittel in Form von Dihydropyridinderivaten enthaltenden Pellets und ihre Herstellung |
DE4221880A1 (de) | 1992-07-03 | 1994-01-05 | Alfatec Pharma Gmbh | Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
JPH11189548A (ja) | 1997-12-25 | 1999-07-13 | Toshio Sato | 無晶性医薬組成物及びその製造方法 |
IL134701A0 (en) | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
CN1235587C (zh) * | 2002-12-12 | 2006-01-11 | 复旦大学 | 9-硝基喜树碱固体分散体及其制备方法 |
WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
WO2009063367A1 (en) | 2007-11-15 | 2009-05-22 | Pfizer Products Inc. | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
WO2011017835A1 (en) * | 2009-08-11 | 2011-02-17 | Nanjing University | Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding |
WO2011031462A2 (en) | 2009-08-25 | 2011-03-17 | Latitude Pharmaceuticals Incorporated | Compositions for delivery of insoluble agents |
AU2012295397A1 (en) * | 2011-08-16 | 2014-02-20 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
CN102327230B (zh) * | 2011-09-30 | 2014-05-21 | 中国药科大学 | 一种包裹紫杉烷类药物的蛋白纳米颗粒及其制备方法 |
WO2015140736A1 (en) * | 2014-03-18 | 2015-09-24 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
GB201416293D0 (en) * | 2014-09-15 | 2014-10-29 | Solvotrin Therapeutics Ltd | Methods and preparations |
-
2017
- 2017-04-28 ES ES17722708T patent/ES2925656T3/es active Active
- 2017-04-28 EP EP22171783.8A patent/EP4062941A1/en active Pending
- 2017-04-28 JP JP2018556473A patent/JP7094226B2/ja active Active
- 2017-04-28 CN CN201780026593.0A patent/CN109152842B/zh active Active
- 2017-04-28 AU AU2017256767A patent/AU2017256767A1/en active Pending
- 2017-04-28 US US16/086,549 patent/US20190083629A1/en not_active Abandoned
- 2017-04-28 CA CA3018812A patent/CA3018812A1/en active Pending
- 2017-04-28 PT PT177227089T patent/PT3448435T/pt unknown
- 2017-04-28 WO PCT/EP2017/060143 patent/WO2017186889A1/en active Search and Examination
- 2017-04-28 BR BR112018072113-1A patent/BR112018072113A2/pt unknown
- 2017-04-28 EP EP17722708.9A patent/EP3448435B1/en active Active
-
2018
- 2018-09-21 ZA ZA2018/06357A patent/ZA201806357B/en unknown
- 2018-10-24 IL IL262568A patent/IL262568A/en unknown
-
2021
- 2021-07-30 US US17/390,185 patent/US20220072136A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508482A (ja) | 1999-09-03 | 2003-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 標的動物に対する水分布システムを通す水−不溶性薬品の投与のための獣医学的調合物 |
JP2007501219A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 薬物及び重合体の固体無定形分散を形成するための噴霧乾燥(スプレードライ)方法 |
Non-Patent Citations (1)
Title |
---|
Enhanced Dispersibility and Bioactivity of Curcumin by Encapsulation in Casein Nanocapsules,J. Agric. Food Chem.,2013年,Vol.61(25),p.6036-6043 |
Also Published As
Publication number | Publication date |
---|---|
JP2019514932A (ja) | 2019-06-06 |
AU2017256767A1 (en) | 2018-10-04 |
CN109152842B (zh) | 2022-10-28 |
CA3018812A1 (en) | 2017-11-02 |
US20220072136A1 (en) | 2022-03-10 |
IL262568A (en) | 2018-12-31 |
EP4062941A1 (en) | 2022-09-28 |
ES2925656T3 (es) | 2022-10-19 |
EP3448435A1 (en) | 2019-03-06 |
ZA201806357B (en) | 2019-07-31 |
PT3448435T (pt) | 2022-07-26 |
US20190083629A1 (en) | 2019-03-21 |
WO2017186889A1 (en) | 2017-11-02 |
BR112018072113A2 (pt) | 2019-02-12 |
CN109152842A (zh) | 2019-01-04 |
EP3448435B1 (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7094226B2 (ja) | 医薬品有効成分用のタンパク質をベースにした添加物 | |
Peñalva et al. | Zein nanoparticles for oral folic acid delivery | |
CA2700426C (en) | Compositions comprising lipophilic active compounds and method for their preparation | |
US10881728B2 (en) | Compositions of food allergens | |
NO332166B1 (no) | Formuleringer av paklitaksel | |
ES2637379T3 (es) | Material polimérico de administración de fármacos, método para fabricar el mismo y método para la administración de una composición de administración de fármacos | |
JPH08509231A (ja) | 修飾加水分解植物タンパク質ミクロスフィア及びその製法と用途 | |
US20190307886A1 (en) | A co-amorphous form of a substance and a protein | |
CA2770334A1 (en) | Orally disintegrating compositions of linaclotide | |
BE1023653B1 (nl) | Eiwit gebaseerd excipient voor actieve farmaceutische stoffen | |
JP2021528498A (ja) | 経口投与用生物学的ポリマーの製剤 | |
JP5841609B2 (ja) | Hcv感染症を処置するための医薬組成物 | |
Sharma et al. | Formulation, in-vitro & in-vivo evaluation of Ethyl cellulose microspheres of Glipizide | |
KR101812520B1 (ko) | 개선된 약제학적 스타터 펠렛 | |
Murugaiyan | Formulation and Evaluation of Domperidone Microparticles | |
Hurtado-Lopez | Zein microspheres: preparation and evaluation as a carrier for vaccine delivery | |
CN1164186A (zh) | 用作治疗载体的经喷雾干燥的微颗粒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20181023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200309 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210812 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220401 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220421 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220530 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220621 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7094226 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |